Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries TriSalus Life Sciences, Inc. - Common Stock (NQ: TLSI ) 4.465 -0.015 (-0.33%) Streaming Delayed Price Updated: 3:09 PM EST, Nov 12, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about TriSalus Life Sciences, Inc. - Common Stock TriSalus Life Sciences® Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav® Infusion System to U.S. Veterans with Liver Cancer November 11, 2024 From TriSalus Life Sciences Via Business Wire TriSalus Life Sciences Launches TriNav® LV Infusion System and TriGuide™ Guiding Catheters, Expanding Portfolio of PEDD™ Devices for Improved Tumor Treatment November 07, 2024 From TriSalus Life Sciences Via Business Wire TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call October 31, 2024 From TriSalus Life Sciences Via Business Wire TriSalus Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit October 14, 2024 From TriSalus Life Sciences Via Business Wire TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board September 26, 2024 From TriSalus Life Sciences Via Business Wire TriSalus Announces Journal of Vascular and Interventional Radiology Publication of Data that Demonstrate Improved Therapeutic Delivery of Glass Microspheres to Solid Tumors With PEDD™ Method via the TriNav® Infusion System September 23, 2024 From TriSalus Life Sciences Via Business Wire TriSalus Reports Q2 2024 Financial Results and Business Update August 15, 2024 From TriSalus Life Sciences Via Business Wire TriSalus Life Sciences to Host Second Quarter 2024 Financial Results Conference Call August 01, 2024 From TriSalus Life Sciences Via Business Wire TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation July 01, 2024 From TriSalus Life Sciences Via Business Wire TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants June 26, 2024 From TriSalus Life Sciences Via Business Wire TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting June 03, 2024 From TriSalus Life Sciences Via Business Wire TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants May 24, 2024 From TriSalus Life Sciences Via Business Wire TriSalus Reports Q1 2024 Financial Results and Business Update May 15, 2024 From TriSalus Life Sciences Via Business Wire TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors May 07, 2024 From TriSalus Life Sciences Via Business Wire TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call May 06, 2024 From TriSalus Life Sciences Via Business Wire TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives April 30, 2024 From TriSalus Life Sciences Via Business Wire TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update April 01, 2024 From TriSalus Life Sciences Via Business Wire TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting March 26, 2024 From TriSalus Life Sciences Via Business Wire TriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting March 21, 2024 From TriSalus Life Sciences Via Business Wire TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association’s Adopted Name Council for “Nelitolimod” as the Nonproprietary Drug Name for SD-101 March 07, 2024 From TriSalus Life Sciences Via Business Wire TriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav® to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver Tumors February 29, 2024 From TriSalus Life Sciences Via Business Wire TriSalus Reports Third Quarter 2023 Financial Results and Provides Business Update November 14, 2023 From TriSalus Life Sciences Inc. Via Business Wire TriSalus Life Sciences to Host Third Quarter 2023 Financial Results Conference Call November 07, 2023 From TriSalus Life Sciences Inc. Via Business Wire Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications November 04, 2023 From TriSalus Life Sciences Inc. Via Business Wire TriSalus Life Sciences Presents Data for SD-101 Delivered by TriSalus Infusion System for Pancreatic Adenocarcinoma at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 03, 2023 From TriSalus Life Sciences Inc. Via Business Wire TriSalus Life Sciences Announces Late Breaker and Additional Data Presentations on Liver Metastases and Pancreatic Cancer at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting October 25, 2023 From TriSalus Life Sciences Via Business Wire TriSalus Life Sciences Appoints Jodi Devlin as President of TriSalus Therapeutics September 06, 2023 From TriSalus Life Sciences Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
